Episode 045: Myeloma Series, Pt.6- Myeloma Treatment in Transplant Ineligible Patients
The Fellow on Call: The Heme/Onc Podcast
00:00
Triplet Therapy for Multiple Myeloma
In the late 90s or early 2000s, we had the lytomide, which was that image drug, and we had Velcade or Bortezamib. And we said, well, let's just do a triplet. Let's do Velcade, Melphalan prednisone, proteasome inhibitor,. against Melphalanprednisone, and it worked. VMP then was superior and became an option for a standard of care in older patients who were transplant ineligible. We also have Dara Tuamab, that CD38 monoclonal antibody. These people are not going to be headed towards a course of high dose alkylater therapy with
Transcript
Play full episode
